315
Participants
Start Date
May 27, 2020
Primary Completion Date
December 31, 2022
Study Completion Date
March 31, 2025
TQB2450
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Anlotinib
a multi-target receptor tyrosine kinase inhibitor
TQB2450(blank)
Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day
Anlotinib(blank)
Subjects administrated anlotinib (blank) in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
NOT_YET_RECRUITING
Peking Union Medical College Hospital, Beijing
NOT_YET_RECRUITING
Jiangsu Cancer Hospital, Nanjing
NOT_YET_RECRUITING
Jiangsu People's Hospital, Nanjing
NOT_YET_RECRUITING
Huaian First People's Hospital, Huai'an
NOT_YET_RECRUITING
Anhui Chest Hospital, Hefei
NOT_YET_RECRUITING
Qilu Hospital of Shandong University, Jinan
NOT_YET_RECRUITING
Tianjin Cancer Hospital, Tianjin
NOT_YET_RECRUITING
The first Hospital of Zhengjiang Province, Hangzhou
RECRUITING
Zhejiang Cancer Hospital, Hangzhou
NOT_YET_RECRUITING
Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou
NOT_YET_RECRUITING
Zhejiang Hospital, Hangzhou
NOT_YET_RECRUITING
Zhejiang People's Hospital, Hangzhou
NOT_YET_RECRUITING
Ningbo Medical Center Lihuili Hospital, Ningbo
NOT_YET_RECRUITING
Taizhou Hospital of Zhejiang Province, Taizhou
NOT_YET_RECRUITING
Taizhou Central Hospital, Taizhou
NOT_YET_RECRUITING
The First Affiliated Hospital of Nanchang University, Nanchang
NOT_YET_RECRUITING
Fujian Cancer Hospital, Fuzhou
RECRUITING
Chongqing University Cancer Hospital, Chongqing
NOT_YET_RECRUITING
The First Affiliated Hospital of Chongqing Medical University, Chongqing
NOT_YET_RECRUITING
Hunan Cancer Hospital, Changsha
NOT_YET_RECRUITING
Xiangya Hospital Central South University, Changsha
NOT_YET_RECRUITING
The Third Xiangya Hospital of Central South University, Changsha
NOT_YET_RECRUITING
Hubei Cancer Hospital, Wuhan
NOT_YET_RECRUITING
Henan Cancer Hospital, Zhengzhou
RECRUITING
Anyang Cancer Hospital, Anyang
RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
NOT_YET_RECRUITING
The First Affiliated Hospital Sun Yat-Sen University, Guangzhou
NOT_YET_RECRUITING
Yuebei People's Hospital, Shaoguan
RECRUITING
The Fifth Affiliated Hospital Sun Yat-Sen University, Zhuhai
NOT_YET_RECRUITING
Affiliated Hospital of Guangdong Medical University, Zhangjiang
NOT_YET_RECRUITING
Guangxi Medical University Affiliated Tumor Hospital, Nanning
NOT_YET_RECRUITING
Xijing Hospital of Airforce Medical University, Xi’an
RECRUITING
First Affiliated Hospital of Xi'anjiantong University, Xi’an
NOT_YET_RECRUITING
Baoji Central Hospital, Baoji
NOT_YET_RECRUITING
The Fourth Hospital of Hebei medical University, Shijiazhuang
NOT_YET_RECRUITING
Shanxi Cancer Hospital, Taiyuan
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY